Document is current
Any future updates will be listed below
-
Authors
Garaudé, Simon http://orcid.org/0000-0003-3474-4895
Marone, Romina http://orcid.org/0000-0003-1474-1689
Lepore, Rosalba http://orcid.org/0000-0002-9481-2557
Devaux, Anna http://orcid.org/0000-0002-5114-9337
Beerlage, Astrid http://orcid.org/0000-0002-0143-544X
Seyres, Denis http://orcid.org/0000-0002-2066-6980
Dell’ Aglio, Alessandro
Juskevicius, Darius
Zuin, Jessica http://orcid.org/0000-0003-3253-1984
Burgold, Thomas http://orcid.org/0009-0006-8324-8934
Wang, Sisi
Katta, Varun http://orcid.org/0000-0002-4565-7335
Manquen, Garret http://orcid.org/0009-0001-2131-1874
Li, Yichao http://orcid.org/0000-0001-5791-096X
Larrue, Clément
Camus, Anna http://orcid.org/0000-0003-2356-5242
Durzynska, Izabela
Wellinger, Lisa C.
Kirby, Ian
Van Berkel, Patrick H. http://orcid.org/0000-0002-7315-0347
Kunz, Christian
Tamburini, Jérôme
Bertoni, Francesco http://orcid.org/0000-0001-5637-8983
Widmer, Corinne C. http://orcid.org/0000-0001-6354-0774
Tsai, Shengdar Q. http://orcid.org/0000-0001-9161-3993
Simonetta, Federico
Urlinger, Stefanie
Jeker, Lukas T. http://orcid.org/0000-0002-3359-8796
- License Information
-
More Information
Article History
Received: 7 August 2023
Accepted: 23 April 2024
First Online: 22 May 2024
Competing interests
: L.T.J. has a sponsored research agreement with Cimeio Therapeutics; the decision to publish was the sole responsibility of L.T.J., whose employer, Basel University Hospital, receives financial compensation for consulting work by L.T.J. I.D., L.C.W and C.K. are employed at Ridgeline Discovery. R.L., A.C. and S.U. are employed at Cimeio Therapeutics. P.H.v.B. is and I.K. was employed at ADC Therapeutics. L.T.J. is a co-founder and board member of Cimeio Therapeutics AG. The University of Basel, R.L., T.B., A.C., I.D., L.C.W., C.K., S.U. and L.T.J. hold equity in Cimeio Therapeutics. P.H.v.B. and I.K. hold equity in ADC Therapeutics. S.G., R.M., R.L., A.D., A.C., I.D., S.U. and L.T.J. are listed as inventors on a patent application related to the findings reported here. C.R.L. and S.Q.T. are inventors on a patent covering CHANGE-seq. S.Q.T. is a member of the scientific advisory board of Prime Medicine and Ensoma. L.T.J. receives: speaker fee from Novartis. F.S. receives: consulting fees from BMS/Celgene, Incyte and Kite/Gilead; speaker fees from Kite/Gilead and Incyte; and travel support from Kite/Gilead, Novartis, AstraZeneca, Neovii and Janssen. F.S. and F.B. receive research funding from Kite/Gilead, Novartis and BMS/Celgene. F.B. receives: institutional research funding from ADC Therapeutics, Bayer, BeiGene, Floratek Pharma, Helsinn, HTG Molecular Diagnostics, Ideogen, Idorsia Pharmaceuticals, Immagene, ImmunoGen, Menarini Ricerche, Nordic Nanovector, Oncternal Therapeutics and Spexis; consultancy fees from BIMINI Biotech, Helsinn and Menarini; advisory board fees to the institution from Novartis; and travel grants from Amgen, Astra Zeneca, Beigene and iOnctura. All other authors declare no competing interests.
